BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lin C, Huang X, Liu H, Wang Y. Interactions of Hepatitis B Virus Infection with Nonalcoholic Fatty Liver Disease: Possible Mechanisms and Clinical Impact. Dig Dis Sci 2015;60:3513-24. [DOI: 10.1007/s10620-015-3772-z] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Zheng Y, Xu K, Hu H, Draz MS, Wu W, Li L. Prevalence and Incidence of Non-alcohol Fatty Liver Disease in Chronic Hepatitis B Population in Southeast China: A Community-Based Study. Front Med (Lausanne) 2021;8:683872. [PMID: 34350196 DOI: 10.3389/fmed.2021.683872] [Reference Citation Analysis]
2 Mak LY, Lee CH, Cheung KS, Wong DK, Liu F, Hui RW, Fung J, Xu A, Lam KS, Yuen MF, Seto WK. Association of adipokines with hepatic steatosis and fibrosis in chronic hepatitis B patients on long-term nucleoside analogue. Liver Int 2019;39:1217-25. [PMID: 30912255 DOI: 10.1111/liv.14104] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
3 Azarkar G, Doosti Z, Osmani F, Ziaee M. Analysis Of Risk Factors For Nonalcoholic Fatty-Liver Disease In Hepatitis B Virus Infection: A Case-Control Study. Hepat Med 2019;11:153-8. [PMID: 31749640 DOI: 10.2147/HMER.S211106] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
4 Gong X, Li T, Wan R, Sha L. Cordycepin attenuates high-fat diet-induced non-alcoholic fatty liver disease via down-regulation of lipid metabolism and inflammatory responses. Int Immunopharmacol 2021;91:107173. [PMID: 33352441 DOI: 10.1016/j.intimp.2020.107173] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Hou J, Chen W, Han Y, Wang L, Lee IH, Hsu LI, Xie D, Yin X, Hou F, Yang Y. Shifting demographics and comorbidity burden in adult Chinese urban patients with chronic hepatitis B, 2013 and 2016. J Comp Eff Res 2021;10:647-57. [PMID: 33970683 DOI: 10.2217/cer-2020-0080] [Reference Citation Analysis]
6 Li J, Yang H, Yeh M, Le MH, Le AK, Yeo YH, Dai C, Barnett S, Zhang JQ, Huang J, Trinh HN, Wong C, Wong C, Hoang JK, Cheung R, Yu M, Nguyen MH. Association Between Fatty Liver and Cirrhosis, Hepatocellular Carcinoma, and Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B. The Journal of Infectious Diseases 2021;224:294-302. [DOI: 10.1093/infdis/jiaa739] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
7 Chen Y, Fan C, Chen Y, Liu H, Wang S, Dong P, Li L, Ding H. Effect of hepatic steatosis on the progression of chronic hepatitis B: A prospective cohort and in vitro study. Oncotarget 2017;8:58601-10. [PMID: 28938582 DOI: 10.18632/oncotarget.17380] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
8 Wong SW, Ting YW, Yong YK, Tan HY, Barathan M, Riazalhosseini B, Bee CJ, Tee KK, Larsson M, Velu V, Shankar EM, Mohamed R. Chronic inflammation involves CCL11 and IL-13 to facilitate the development of liver cirrhosis and fibrosis in chronic hepatitis B virus infection. Scand J Clin Lab Invest 2021;81:147-59. [PMID: 33528280 DOI: 10.1080/00365513.2021.1876245] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Zhang J, Lin S, Jiang D, Li M, Chen Y, Li J, Fan J. Chronic hepatitis B and non-alcoholic fatty liver disease: Conspirators or competitors? Liver Int 2020;40:496-508. [PMID: 31903714 DOI: 10.1111/liv.14369] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
10 Zhang GL, Xu SC, Zeng J, Chen Z, Li YP, Zhang T, Gao ZL. Optimizing the Use of the Gamma-Glutamyl Transpeptidase-to-Platelet Ratio and Transient Elastography to Identify Liver Cirrhosis in Patients with Chronic Hepatitis B Concurrent with Nonalcoholic Fatty Liver Disease. Dis Markers 2019;2019:2585409. [PMID: 31885733 DOI: 10.1155/2019/2585409] [Reference Citation Analysis]
11 Mak L, Seto W, Fung J, Yuen M. Novel developments of hepatitis B: treatment goals, agents and monitoring tools. Expert Review of Clinical Pharmacology 2019;12:109-20. [DOI: 10.1080/17512433.2019.1567327] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
12 Zhu L, Jiang J, Zhai X, Baecker A, Peng H, Qian J, Zhou M, Song C, Zhou Y, Xu J, Liu H, Hang D, Hu Z, Shen H, Zhang ZF, Zhu F. Hepatitis B virus infection and risk of non-alcoholic fatty liver disease: A population-based cohort study. Liver Int. 2019;39:70-80. [PMID: 30025200 DOI: 10.1111/liv.13933] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 6.7] [Reference Citation Analysis]
13 Li J, Le AK, Chaung KT, Henry L, Hoang JK, Cheung R, Nguyen MH. Fatty liver is not independently associated with the rates of complete response to oral antiviral therapy in chronic hepatitis B patients. Liver Int. 2020;40:1052-1061. [PMID: 32086988 DOI: 10.1111/liv.14415] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
14 Nguyen MH, Lim JK, Burak Ozbay A, Fraysse J, Liou I, Meyer N, Dusheiko G, Gordon SC. Advancing Age and Comorbidity in a US Insured Population-Based Cohort of Patients With Chronic Hepatitis B. Hepatology. 2019;69:959-973. [PMID: 30175482 DOI: 10.1002/hep.30246] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 14.0] [Reference Citation Analysis]
15 Chen Q, Zhao L, Mei L, Zhong R, Han P, Yang H, Li Q, Li J. Association of sex hormones with hepatic steatosis in men with chronic hepatitis B. Dig Liver Dis 2021:S1590-8658(21)00273-5. [PMID: 34116975 DOI: 10.1016/j.dld.2021.05.022] [Reference Citation Analysis]
16 Zhu Y, Yang Q, Lv F, Yu Y. The Effect of Hepatosteatosis on Response to Antiviral Treatment in Patients with Chronic Hepatitis B: A Meta-Analysis. Gastroenterol Res Pract. 2017;2017:1096406. [PMID: 28421108 DOI: 10.1155/2017/1096406] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
17 Mak LY, Hui RW, Fung J, Liu F, Wong DK, Cheung KS, Yuen MF, Seto WK. Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B. J Hepatol. 2020;73:800-806. [PMID: 32504663 DOI: 10.1016/j.jhep.2020.05.040] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 13.0] [Reference Citation Analysis]
18 Joo EJ, Chang Y, Yeom JS, Ryu S. Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: A cohort study. Hepatology. 2017;65:828-835. [PMID: 28035771 DOI: 10.1002/hep.28917] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 10.8] [Reference Citation Analysis]
19 Joo E, Chang Y, Yeom J, Cho YK, Ryu S. Chronic hepatitis B virus infection and risk of dyslipidaemia: A cohort study. J Viral Hepat 2019;26:162-9. [DOI: 10.1111/jvh.13014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
20 Zhang J, Ling N, Lei Y, Peng M, Hu P, Chen M. Multifaceted Interaction Between Hepatitis B Virus Infection and Lipid Metabolism in Hepatocytes: A Potential Target of Antiviral Therapy for Chronic Hepatitis B. Front Microbiol 2021;12:636897. [PMID: 33776969 DOI: 10.3389/fmicb.2021.636897] [Reference Citation Analysis]
21 Oh JH, Lee HW, Sinn DH, Park JY, Kim BK, Kim SU, Kim DY, Ahn SH, Kang W, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Paik YH. Controlled attenuation parameter value and the risk of hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy. Hepatol Int 2021;15:892-900. [PMID: 34260013 DOI: 10.1007/s12072-021-10205-7] [Reference Citation Analysis]
22 Nakatsuka T, Tateishi R, Koike K. Changing clinical management of NAFLD in Asia. Liver Int 2021. [PMID: 34459096 DOI: 10.1111/liv.15046] [Reference Citation Analysis]
23 Zhang GL, Zhao QY, Lin CS, Hu ZX, Zhang T, Gao ZL. Transient Elastography and Ultrasonography: Optimal Evaluation of Liver Fibrosis and Cirrhosis in Patients with Chronic Hepatitis B Concurrent with Nonalcoholic Fatty Liver Disease. Biomed Res Int 2019;2019:3951574. [PMID: 30809540 DOI: 10.1155/2019/3951574] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
24 Fong TL, Lee BT, Chang M, Nasanbayar K, Tsogtoo E, Boldbaatar D, Dashdorj ED, Clifford NE, Dashdorj AN, Bang BR, Chida T, Lim C, Sugiyama M, Mizokami M, Dashdorj NJ, Liu P, Glenn JS, Dashdorj ND, Saito T. High Prevalence of Chronic Viral Hepatitis and Liver Fibrosis Among Mongols in Southern California. Dig Dis Sci 2021;66:2833-9. [PMID: 32770488 DOI: 10.1007/s10620-020-06499-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
25 Huang X, Chen W, Yan C, Yang R, Chen Q, Xu H, Huang Y. Gypenosides improve the intestinal microbiota of non-alcoholic fatty liver in mice and alleviate its progression. Biomedicine & Pharmacotherapy 2019;118:109258. [DOI: 10.1016/j.biopha.2019.109258] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]